The purpose of this paper is to report the increasing incidence of contact-lens related Acanthamoeba keratitis (AK) in a tertiary ophthalmology department in Umbria, central Italy.
Methods
Observational and retrospective case series were carried out. A total of nine eyes with a diagnosis of AK were examined. All patients underwent a full slit lamp examination, in vivo confocal microscopy (IVCM) and corneal scraping. The IVCM was repeated at one and two-week and at one, three and six-month intervals. Samples of domestic tap water were also examined for PCR analysis. Patients were treated with levofloxacin0,5%, Polyhexamethylene biguanide 0.02%, and Propamidine Isetionate0,1%.
Results
All patients were contact lens wearers. The average patient age was 27.75 (range 18–45), with three men and five women. The main clinical features were ciliary congestion, diffuse epitheliopathy with punctuated keratitis, multiple, small sub-epithelial, greyish, corneal infiltrates with epithelial defect, pseudodendritic corneal lesions, perineural infiltrates, corneal stromal cellularity, and stromal infiltrates. IVCM was indicative of Acanthamoeba in seven out of the nine eyes. All the positive IVCM images were section images showing double walled, bright-spot cysts with a clear chain-like arrangement of five or more cysts identified in three of the patients. PCR analysis of the water was negative in all cases.
Conclusion
Although PCR is the most common method used, the increased incidence of AK could mainly be related to a proper IVCM interpretation. A broad-spectrum antibiotic, such as levofloxacin might play a role in the early treatment of AK reducing the virulence of the amoeba.
KaufmanARTuEY. Advances in the management of Acanthamoeba keratitis: a review of the literature and synthesized algorithmic approach: advances in the Management of Acanthamoeba. Ocul Surf2022; 25: 26–36. https://doi.org/10.1016/j.jtos.2022.04.003
2.
Lorenzo-MoralesJKhanNAWalochnikJ. An update on Acanthamoeba keratitis: Diagnosis, pathogenesis and treatment. Parasite2015; 22: 10.
3.
TingDSJHoCSDeshmukhR, et al.Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye2021; 35: 1084–1101.
4.
DartJKGSawVPJKilvingtonS. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol2009; 148: 487–499.e2. https://doi.org/10.1016/j.ajo.2009.06.009
5.
ZhangYXuXWeiZ, et al.The global epidemiology and clinical diagnosis of Acanthamoeba keratitis. J Infect Public Health2023; 16: 841–852.
6.
RayamajheeBWillcoxMDHenriquezFL, et al.Acanthamoeba keratitis: an increasingly common infectious disease of the cornea. Lancet Microbe2021; 2: e345–e346.
RammohanRBaidwalSVenkatapathyN, et al.A 5-year review of coinfections in Acanthamoeba keratitis from south India. Eye Contact Lens2023; 49: 334–338. https://doi.org/10.1097/ICL.0000000000001005
9.
RayamajheeBSharmaSWillcoxM, et al.Assessment of genotypes, endosymbionts and clinical characteristics of Acanthamoeba recovered from ocular infection. BMC Infect Dis2022; 22: 757. https://doi.org/10.1186/s12879-022-07741-4
10.
ScruggsBAQuistTSZimmermanMB, et al.Risk factors, management, and outcomes of Acanthamoeba keratitis: A retrospective analysis of 110 cases. Am J Ophthalmol Case Reports2022; 25: 101372. https://doi.org/10.1016/j.ajoc.2022.101372
11.
RayamajheeBWillcoxMDPHenriquezFL, et al.Acanthamoeba, an environmental phagocyte enhancing survival and transmission of human pathogens. Trends Parasitol2022; 38: 975–990.
12.
LeckA. Taking a corneal scrape and making a diagnosis. Community Eye Heal J2015; 22: 8–9.
13.
Abd El WahabWMEl-BadryAAHamdyDA. Molecular characterization and phylogenetic analysis of Acanthamoeba isolates in tap water of Beni-Suef, Egypt. Acta Parasitol2018; 63: 826–834. https://doi.org/10.1515/ap-2018-0101
14.
SchroederJMBootonGCHayJ, et al.Use of subgenic 18S ribosomal DNA PCR and sequencing for genus and genotype identification of Acanthamoebae from humans with keratitis and from sewage sludge. J Clin Microbiol2001; 39: 1903–1911. https://doi.org/10.1128/JCM.39.5.1903-1911.2001
15.
AlomarTMatthewMDonaldF, et al.In vivo confocal microscopy in the diagnosis and management of Acanthamoeba keratitis showing new cystic forms. Clin Exp Ophthalmol2009; 37: 737–739.
16.
LiSBianJWangY, et al.Clinical features and serial changes of Acanthamoeba keratitis: an in vivo confocal microscopy study. Eye2020; 34: 327–334. https://doi.org/10.1038/s41433-019-0482-3
17.
KhanNA. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol Rev2006; 30: 564–595.
18.
GuimaraesAJGomesKXCortinesJR, et al.Acanthamoeba spp. as a universal host for pathogenic microorganisms: one bridge from environment to host virulence. Microbiol Res2016; 193: 30–38.
19.
RayamajheeBSubediDPegudaHK, et al.A systematic review of intracellular microorganisms within Acanthamoeba to understand potential impact for infection. Pathogens2021; 10: 225.
20.
LiWWangZQuJ, et al.Acanthamoeba keratitis related to contact lens use in a tertiary hospital in China. BMC Ophthalmol2019; 19: 1210–1212. https://doi.org/10.1186/s12886-019-1210-2
21.
AntonelliAFavuzzaEGalanoA, et al.Regional spread of contact lens-related Acanthamoeba keratitis in Italy. New Microbiologica2018; 41: 83–85.
22.
Rodríguez-MartínJRocha-CabreraPReyes-BatlleM, et al.Presence of Acanthamoeba in the ocular surface in a Spanish population of contact lens wearers. Acta Parasitol2018; 63: 393–396. https://doi.org/10.1515/ap-2018-0045
OmariAAMianSI. Adenoviral keratitis: a review of the epidemiology, pathophysiology, clinical features, diagnosis, and management. Curr Opin Ophthalmol2018; 29: 365–372.
27.
BrownLLeckAKGichangiM, et al.The global incidence and diagnosis of fungal keratitis. Lancet Infect Dis2021; 21: e49–e57.
28.
LindquistTDSherNADoughmanDJ. Clinical signs and medical therapy of early Acanthamoeba keratitis. Arch Ophthalmol1988; 106: 73–77.
29.
KowalskiRPMelanMAKarenchakLM,et al.Comparison of validated polymerase chain reaction and culture isolation for the routine detection of Acanthamoeba from ocular samples. Eye Contact Lens2015; 41: 341–343. https://doi.org/10.1097/ICL.0000000000000131
30.
NiedererRLMcGheeCNJ. Clinical in vivo confocal microscopy of the human cornea in health and disease. Prog Retin Eye Res2010; 29: 30–58.
31.
GohJWYHarrisonRHauS, et al.Comparison of in vivo confocal microscopy, PCR and culture of corneal scrapes in the diagnosis of Acanthamoeba keratitis. Cornea2018; 37: 480–485. https://doi.org/10.1097/ICO.0000000000001497
32.
TuEYJoslinCESugarJ, et al.The relative value of confocal microscopy and superficial corneal scrapings in the diagnosis of Acanthamoeba keratitis. Cornea2008; 27: 764–772. https://doi.org/10.1097/ICO.0b013e31816f27bf
33.
WangYETepelusTCGuiW, et al.Reduction of Acanthamoeba cyst density associated with treatment detected by in vivo confocal microscopy in Acanthamoeba keratitis. Cornea2019; 38: 463–468. https://doi.org/10.1097/ICO.0000000000001857
34.
NakagawaHHattoriTKoikeN, et al.Investigation of the role of bacteria in the development of Acanthamoeba keratitis. Cornea2015; 34: 1308–1315. https://doi.org/10.1097/ICO.0000000000000541
35.
HeaselgraveWHamadAColesS,et al.In vitro evaluation of the inhibitory effect of topical ophthalmic agents on Acanthamoeba viability. Transl Vis Sci Technol2019; 8: 17. https://doi.org/10.1167/tvst.8.5.17
36.
ThongseesuksaiTWongwaiPBoonmarsT, et al.Evaluating the in vitro efficacy of gatifloxacin, levofloxacin and gentamicin against Acanthamoeba cysts. Int Ophthalmol2020; 40: 361–368. https://doi.org/10.1007/s10792-019-01188-4
37.
IovienoALedeeDRMillerD,et al.Detection of bacterial endosymbionts in clinical Acanthamoeba isolates. Ophthalmology2010; 117: 445–452.e3. https://doi.org/10.1016/j.ophtha.2009.08.033
38.
PurssellALauRBoggildAK. Azithromycin and doxycycline attenuation of Acanthamoeba virulence in a human corneal tissue model. J Infect Dis2017; 215: 1303–1311. https://doi.org/10.1093/infdis/jiw410
NakagawaHHattoriTKoikeN, et al.Number of bacteria and time of coincubation with bacteria required for the development of Acanthamoeba keratitis. Cornea2017; 36: 353–357. https://doi.org/10.1097/ICO.0000000000001129
41.
LimNGohDBunceC, et al.Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol2008; 145: 130–135. https://doi.org/10.1016/j.ajo.2007.08.040
42.
RobertsCWHenriquezFL. Drug target identification, validation, characterisation and exploitation for treatment of Acanthamoeba (species) infections. Exp Parasitol2010; 126: 91–96. https://doi.org/10.1016/j.exppara.2009.11.016
43.
PerrineDChenuJPGeorgesP, et al.Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. Antimicrob Agents Chemother1995; 39: 339–342. https://doi.org/10.1128/aac.39.2.339
MusayevaARiedlJCSchusterAK, et al.Topical voriconazole as supplemental treatment for Acanthamoeba keratitis. Cornea2020; 39: 986–990. https://doi.org/10.1097/ICO.0000000000002315
46.
DartJKGPapaVRamaP, et al.The orphan drug for Acanthamoeba keratitis (ODAK) trial: PHMB 0.08% (polihexanide) and placebo versus PHMB 0.02% and propamidine 0.1. Ophthalmology2024; 131: 277–287. https://doi.org/10.1016/j.ophtha.2023.09.031
47.
WoutersKAVerhoekxJSNvan RooijJ, et al.Topical corticosteroids in Acanthamoeba keratitis: friend or foe?Eur J Ophthalmol2022; 32: 170–175. https://doi.org/10.1177/1120672120973606
